About Torque

Torque is developing a new class of Deep-Primed™ T cell therapeutics to dramatically expand cell therapy cures for cancer.

Our Deep-Priming technology platform uses advanced cell process engineering to:

  1. prime and activate T cells to target multiple tumor antigens, and
  2. tether immune-stimulatory drugs directly to the surface of these multi-target T cells to stimulate and direct the immune response locally in the tumor microenvironment.

These Deep-Primed T cells both target multiple tumor antigens and pharmacologically activate an immune response with anchored cytokines. This process does not require genetic engineering of the T cells and so preserves the natural T cell receptor for delivering a regulated immune response, with the potential for a high margin of safety.

Torque Deep-Primed cell therapeutics have the potential to be foundational therapy for both solid and hematologic tumors, addressing the two fundamental challenges of immunotherapy:

  1. Tumors with heterogeneous antigens that readily develop resistance to single-target therapy
  2. Immunosuppressive tumor microenvironments that limit T cell function, persistence, and trafficking

In hematologic cancers, this new class of immune therapeutics has the potential to improve on the initial success of single-target CAR-T therapeutics with expanded efficacy, and also move cell therapy treatment out of the hospital with a high margin of safety. For solid tumors, Deep-Primed T cells have the potential to enable efficacy against tumors with heterogeneous antigens protected by hostile microenvironments, which are not readily addressable with the first generation of immune cell therapies.

We have completed preclinical studies with our initial clinical candidate—Deep IL-15 Primed T Cells—that demonstrate increased T cell proliferation, engraftment, and tumor cell killing, including the potential to improve on pre-conditioning regimens. We will initiate the first clinical trials of Deep IL-15 in 2018.

Back to Top